% | $
Quotes you view appear here for quick access.

ESSA Pharma Inc. Message Board

  • thirdmeinvestor thirdmeinvestor Mar 12, 2005 12:14 PM Flag


    Q. What differentiates MS-325 from conventional MRI imaging pharmaceuticals?
    A. Conventional MRI imaging pharmaceuticals, commonly referred to as extracellular contrast, leak rapidly from the bloodstream into the extracellular fluid. As a result, imaging must be completed within seconds, which limits their application and often requires multiple injections for visualization of multiple vascular regions. By contrast, MS-325 binds to serum albumin in the blood, providing a bright image of the blood vessels for an extended period of time, and is safely excreted by the kidneys. Thus, MS-325 enables longer data collection times, yielding a comprehensive set of high-resolution images without the technical challenge of scan timing as conventional contrast flows throughout the body. After a single injection, this intravascular imaging pharmaceutical has the potential to enable a survey of many vascular regions in one MRI examination.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.9660.000(0.00%)May 3 3:41 PMEDT